Sofinnova Partners Archives

News and Trends 13 Aug 2020

Why are Some European Biotechs Going Public Without an IPO?

European biotech companies are flocking to the Nasdaq Stock Market in 2020, but not all are going the traditional Initial Public Offering (IPO) route. What does this mean for the dominance of the biotech IPO in Europe? In spite of the Covid-19 pandemic, biotech IPOs have continued unabated. In fact, a report from Bioworld found […]

August 13, 2020 - 7 minutesmins - By Jonathan Smith

News and Trends 15 Jun 2020

Chilean Biotech Moves to France to Develop Anti-Mold Food Preservative

The startup Protera is moving from Santiago de Chile to Paris following a €5M Series A round that will let the company scale up the production of an antifungal protein food preservative to the pilot scale. The Series A round was led by the European venture capital firm Sofinnova Partners, and will allow the company […]

June 15, 2020 - 4 minutesmins - By David Kirk

News and Trends 27 Apr 2020

Series A Round Boosts Swedish Synthetic Biology Player by €6.4M

The Swedish synthetic biology company EnginZyme has raised a Series A funding round to the tune of €6.4M to develop its cell-free synbio technology for the sustainable production of plastic, rubber, and other synthetic materials. The latest investment, which was led by French venture fund Sofinnova Partners, brings EnginZyme’s total funding to more than €10M […]

April 27, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

Orchard therapeutics gene therapy header

News and Trends 23 Apr 2020

Sofinnova Invests €20M in Three Italian Rare Disease Biotechs

The French VC firm Sofinnova Partners has invested €20M in three Italian biotech companies via its Telethon Fund, which focuses on firms developing treatments for rare diseases. The deals by the Sofinnova Telethon Fund were made over the last several months. The companies the Fund invested in — Genespire, Epsilen Bio, and PinCell — are […]

April 23, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 16 Jan 2020

Biotech Investment Firm Jeito Capital Launches with €200M Fund

The French investment firm Jeito Capital has launched this week with a €200M fund that will support up to 15 drug-development start-ups with a focus on European companies. Jeito Capital is the brainchild of Rafaèle Tordjman, whose background in medicine and research as well as investment in life sciences led her to setting up the […]

January 16, 2020 - 2 minutesmins - By External Contributor

Expert Advice 15 Jan 2020

How to Spot a Biotech Winner: Investment Lessons from Sofinnova

Making one biotech a success is hard enough, but correctly predicting multiple winners is the bread and butter of Antoine Papiernik, Managing Partner of Sofinnova Partners, one of the biggest and most prosperous life science venture capital investors in Europe. Papiernik began his career in corporate finance. In 1995, he was working in investment in […]

January 15, 2020 - 10 minutesmins - By Helen Albert

In Depth 14 Jan 2020

What’s the Secret to Making Returns in Industrial Biotech?

As industrial biotech starts gaining more and more traction, investors need to change their mindset in order to start making returns in this promising field. Microorganisms have been helping us make food and drink since ancient times. Thanks to the industrial biotech revolution, these microbes could soon be responsible for manufacturing anything from clothing to […]

January 14, 2020 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 20 Nov 2019

€39M Series B to Fund Biopolymers for Surgery and Implants

The French company Tissium has raised a €38.8M Series B round to fund the development of polymers that can be used to repair blood vessels and nerves. Contributing to the round were newcomers to Tissium such as the European Investment Fund and returning investors such as the investment bank Bpifrance and French life sciences […]

November 20, 2019 - 2 minutesmins - By Jonathan Smith

More News! 17 Oct 2019

Sofinnova Partners Raises €333M for its Newest Life Sciences-Focused Fund

Sofinnova Partners, Europe’s largest VC focused on life sciences, has raised €333M to fund early-stage healthcare companies, bringing the total capital managed by the firm to €2B. Sofinnova Partners aims to invest around two-thirds of the new fund, called Sofinnova Capital IX, in European life science companies. The other third will be invested globally, with […]

October 17, 2019 - 2 minutesmins - By Jonathan Smith

Interview 8 Oct 2019

Biotech Hubs: A Tale of Two Cities

Life science investors differ widely across biotech hubs in Europe. At Labiotech’s recent Refresh event, two investors from Cambridge and Paris compared the progress of these hubs and discussed the challenges that need to be overcome in biotech investment. Funding is the lifeblood of early biotech startups, and investors are a crucial supplier. For this […]

October 8, 2019 - 6 minutesmins - By Jonathan Smith

Opinion 16 Jul 2019

The Business of Biotech: What to Do When the S*#t Hits the Fan

From CEO-itis to FDA-itis, the path of a biotech company is never dull. Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends entirely on your perspective. As a life science venture capital investor with close to 25 years of experience, I have encountered many unexpected and interesting […]

July 16, 2019 - 5 minutesmins - By Antoine Papiernik

More News! 23 May 2018

Danish Biotech Raises Series A Round to Advance Microbe Engineering Technology

Biosyntia has raised €4M in Series A financing from Sofinnova Partners to bring its microbe engineering technology closer to commercialization. Biosyntia, based in Copenhagen, has raised €4M in Series A financing to continue developing its biosynthetic selection technology to produce complex compounds by fermentation. The funding was provided by Sofinnova Partners, a new investor and leading European […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us